JPRN-UMIN000003033
Completed
未知
Global Assessment Study of Anti-cholinergics on Efficacy and Tolerability for Patients with OAB - GAP Study
GAP Study Group0 sites300 target enrollmentApril 14, 2010
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- GAP Study Group
- Enrollment
- 300
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\)Genuine stress incontinence. (2\)Prostate cancer, bladder cancer, urinary tract stones, symptomatic urinary tract infection, recurrent urinary tract infection and interstitial cystitis. (3\)Indwelling or intermittent urethral catheterization. (4\)Polyuria. (5\)Lower urinary tract symptom is unstable. (6\)Serious heart failure, serious liver failure and serious kidney failure. (7\)Contraindications to antimusucarinic agents. (8\)Sjogren's syndrome or hyposalivation by RT. (9\)Treatment with banned medicine within 2 weeks before the run\-in period. (10\)Electric stimulation therapy or bladder training within 3 months before the run\-in period. (11\)Genitourinary surgery within 6 months before the run\-in period. (12\)Any other cases who are regarded as inadequate for study enrollment by the investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Evaluation of the usefulness of anti-cholinergic and B(Beta)3 agonist in patients with OAB.Overactive bladderJPRN-UMIN000008863Clinical Research Support Center Kyushu400
Completed
Not Applicable
Study on the safety and efficacy of anticolinergics for children with overactive bladderPediatric overactive bladderJPRN-UMIN000017267Department of Renal and Urologic Surgery, Asahikawa Medical University150
Active, not recruiting
Phase 1
Impact of anticholinergic treatment on urinary discomfort during radiotherapy for prostate cancerSymptomatology related to acute urinary toxicity occuring during prostate irradiation in patients suffering from prostate cancer.MedDRA version: 18.1Level: HLTClassification code 10004995Term: Bladder and urethral symptomsSystem Organ Class: 100000004857Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]EUCTR2014-004296-22-FRCentre Eugène Marquis
Completed
Phase 3
Effect of Anticholinergic Drug On uroflowmetryBenign Prostatic Hyperplasia.Enlarged prostateIRCT20190928044913N1Sabzevar University of Medical Sciences60
Active, not recruiting
Phase 1
A cohort study of anticholinergic drugs in South Asian women with detrusor overactivityEUCTR2006-001210-33-GBniversity Hospitals of Leicester NHS Trust50